A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

Gunilla Enblad; Hans Hagberg; Martin Erlanson; Jeanette Lundin; Anja Porwit MacDonald; Roland Repp; Johannes Schetelig; Gernot Seipelt; Anders Osterborg

doi:10.1182/blood-2003-10-3389

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

Identifier:nobleid.org/w1/20260515/AA474DDF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AA474DDF.svg?ark=w1%2F20260515%2FAA474DDF)](https://nobleid.org/work/w1/20260515/AA474DDF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Anja Porwit MacDonald

Claim authorship of this work

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

Identifier:nobleid.org/w1/20260515/AA474DDF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AA474DDF.svg?ark=w1%2F20260515%2FAA474DDF)](https://nobleid.org/work/w1/20260515/AA474DDF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Anja Porwit MacDonald

Claim authorship of this work